TY - JOUR
T1 - Clonal heterogeneity of lymphoid malignancies correlates with poor prognosis
AU - Suguro, Miyuki
AU - Yoshida, Noriaki
AU - Umino, Akira
AU - Kato, Harumi
AU - Tagawa, Hiroyuki
AU - Nakagawa, Masao
AU - Fukuhara, Noriko
AU - Karnan, Sivasundaram
AU - Takeuchi, Ichiro
AU - Hocking, Toby D.
AU - Arita, Kotaro
AU - Karube, Kennosuke
AU - Tsuzuki, Shinobu
AU - Nakamura, Shigeo
AU - Kinoshita, Tomohiro
AU - Seto, Masao
PY - 2014/7
Y1 - 2014/7
N2 - Clonal heterogeneity in lymphoid malignancies has been recently reported in adult T-cell lymphoma/leukemia, peripheral T-cell lymphoma, not otherwise specified, and mantle cell lymphoma. Our analysis was extended to other types of lymphoma including marginal zone lymphoma, follicular lymphoma and diffuse large B-cell lymphoma. To determine the presence of clonal heterogeneity, 332 cases were examined using array comparative genomic hybridization analysis. Results showed that incidence of clonal heterogeneity varied from 25% to 69% among different types of lymphoma. Survival analysis revealed that mantle cell lymphoma and diffuse large B-cell lymphoma with clonal heterogeneity showed significantly poorer prognosis, and that clonal heterogeneity was confirmed as an independent predictor of poor prognosis for both types of lymphoma. Interestingly, 8q24.1 (MYC) gain, 9p21.3 (CDKN2A/2B) loss and 17p13 (TP53, ATP1B2, SAT2, SHBG) loss were recurrent genomic lesions among various types of lymphoma with clonal heterogeneity, suggesting at least in part that alterations of these genes may play a role in clonal heterogeneity. In this issue of Cancer Science, Suguro et al. have developed a method for the assessment of clonal heterogeneity base on array CGH analysis. 332 cases comprising six types of lymphoma were investigated the presence of clonal heterogeneity. Cases with clonal heterogeneity showed poor prognosis and recurrent genomic copy number alterations of MYC, CDKN2A/2B, and TP53 irrespective lymphoma type.
AB - Clonal heterogeneity in lymphoid malignancies has been recently reported in adult T-cell lymphoma/leukemia, peripheral T-cell lymphoma, not otherwise specified, and mantle cell lymphoma. Our analysis was extended to other types of lymphoma including marginal zone lymphoma, follicular lymphoma and diffuse large B-cell lymphoma. To determine the presence of clonal heterogeneity, 332 cases were examined using array comparative genomic hybridization analysis. Results showed that incidence of clonal heterogeneity varied from 25% to 69% among different types of lymphoma. Survival analysis revealed that mantle cell lymphoma and diffuse large B-cell lymphoma with clonal heterogeneity showed significantly poorer prognosis, and that clonal heterogeneity was confirmed as an independent predictor of poor prognosis for both types of lymphoma. Interestingly, 8q24.1 (MYC) gain, 9p21.3 (CDKN2A/2B) loss and 17p13 (TP53, ATP1B2, SAT2, SHBG) loss were recurrent genomic lesions among various types of lymphoma with clonal heterogeneity, suggesting at least in part that alterations of these genes may play a role in clonal heterogeneity. In this issue of Cancer Science, Suguro et al. have developed a method for the assessment of clonal heterogeneity base on array CGH analysis. 332 cases comprising six types of lymphoma were investigated the presence of clonal heterogeneity. Cases with clonal heterogeneity showed poor prognosis and recurrent genomic copy number alterations of MYC, CDKN2A/2B, and TP53 irrespective lymphoma type.
KW - Array comparative genomic hybridization
KW - Heterogeneity
KW - Malignant lymphoma
KW - Patient outcome assessment
KW - Tumor cell population
UR - http://www.scopus.com/inward/record.url?scp=84904251500&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84904251500&partnerID=8YFLogxK
U2 - 10.1111/cas.12442
DO - 10.1111/cas.12442
M3 - Article
C2 - 24815991
AN - SCOPUS:84904251500
SN - 1347-9032
VL - 105
SP - 897
EP - 904
JO - Cancer Science
JF - Cancer Science
IS - 7
ER -